Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | https://doi.org/10.4084/mjhid.2016.024 http://hdl.handle.net/1843/61942 https://orcid.org/0000-0001-8573-6313 |
Resumo: | Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatment strategies for childhood ALL result in long term remission for approximately 90% of patients. However, therapeutic response is worse among those who relapse. Several risk stratification approaches based on clinical and biological aspects have been proposed in order to intensify treatment in patients with high risk of relapse and reduce toxicity on those with greater probability of cure. The detection of residual leukemic cells (minimal residual disease, MRD) is the most important prognostic factor to identify high risk patients, allowing redefinition of chemotherapy. In the last decades, several standardized research protocols evaluated MRD using immunophenotyping by flow cytometry and/or real time quantitative polymerase chain reaction at different time points during treatment. Both methods are highly sensitive (10-3 a 10-5), but expensive, complex, and, because of that, require qualified staff and frequently are restricted to reference centers. The aim of this article was to review technical aspects of immunophenotyping by flow cytometry and real time quantitative polymerase chain reaction to evaluate MRD in ALL. |
id |
UFMG_ee40ab23699076dcde6cc3bb64fbde7c |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/61942 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2023-12-12T20:23:08Z2023-12-12T20:23:08Z20168https://doi.org/10.4084/mjhid.2016.0242035-3006http://hdl.handle.net/1843/61942https://orcid.org/0000-0001-8573-6313Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatment strategies for childhood ALL result in long term remission for approximately 90% of patients. However, therapeutic response is worse among those who relapse. Several risk stratification approaches based on clinical and biological aspects have been proposed in order to intensify treatment in patients with high risk of relapse and reduce toxicity on those with greater probability of cure. The detection of residual leukemic cells (minimal residual disease, MRD) is the most important prognostic factor to identify high risk patients, allowing redefinition of chemotherapy. In the last decades, several standardized research protocols evaluated MRD using immunophenotyping by flow cytometry and/or real time quantitative polymerase chain reaction at different time points during treatment. Both methods are highly sensitive (10-3 a 10-5), but expensive, complex, and, because of that, require qualified staff and frequently are restricted to reference centers. The aim of this article was to review technical aspects of immunophenotyping by flow cytometry and real time quantitative polymerase chain reaction to evaluate MRD in ALL.A leucemia linfoblástica aguda (LLA) é o câncer mais comum em crianças. As estratégias atuais de tratamento para LLA infantil resultam em remissão a longo prazo para aproximadamente 90% dos pacientes. No entanto, a resposta terapêutica é pior entre aqueles que recaem. Diversas abordagens de estratificação de risco baseadas em aspectos clínicos e biológicos têm sido propostas a fim de intensificar o tratamento em pacientes com alto risco de recaída e reduzir a toxicidade naqueles com maior probabilidade de cura. A detecção de células leucêmicas residuais (doença residual mínima, DRM) é o fator prognóstico mais importante para identificar pacientes de alto risco, permitindo a redefinição da quimioterapia. Nas últimas décadas, vários protocolos de pesquisa padronizados avaliaram a DRM usando imunofenotipagem por citometria de fluxo e/ou reação em cadeia da polimerase quantitativa em tempo real em diferentes momentos durante o tratamento. Ambos os métodos são altamente sensíveis (10-3 a 10-5), porém caros, complexos e, por isso, exigem pessoal qualificado e muitas vezes ficam restritos a centros de referência. O objetivo deste artigo foi revisar aspectos técnicos da imunofenotipagem por citometria de fluxo e reação em cadeia da polimerase quantitativa em tempo real para avaliar DRM na LLA.engUniversidade Federal de Minas GeraisUFMGBrasilMED - DEPARTAMENTO DE PEDIATRIAMediterranean journal of hematology and infectious diseasesNeoplasia residualLeucemia-linfoma linfoblástico de células precursorasCitometria de fluxoReação em cadeia da polimeraseRearranjo gênico do linfócito TMinimal residual diseaseAcute lymphoblastic leukemiaFlow cytometryPCRGene rearrangements of Ig/TCRCurrent strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemiaEstratégias atuais para a detecção de doença residual mínima na leucemia linfoblástica aguda infantilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.mjhid.org/index.php/mjhid/article/view/2016.024Juliana Maria Camargos RochaSandra Guerra XavierMarcelo Eduardo Lima SouzaJuliana Godoy AssumpçãoMitiko MuraoBenigna Maria de Oliveiraapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/61942/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALCurrent strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.pdfCurrent strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.pdfapplication/pdf307972https://repositorio.ufmg.br/bitstream/1843/61942/2/Current%20strategies%20for%20the%20detection%20of%20minimal%20residual%20disease%20in%20childhood%20acute%20lymphoblastic%20leukemia.pdfb43bc464ca470f4275e09cfda71274fdMD521843/619422023-12-12 17:23:09.103oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-12-12T20:23:09Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia |
dc.title.alternative.pt_BR.fl_str_mv |
Estratégias atuais para a detecção de doença residual mínima na leucemia linfoblástica aguda infantil |
title |
Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia |
spellingShingle |
Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia Juliana Maria Camargos Rocha Minimal residual disease Acute lymphoblastic leukemia Flow cytometry PCR Gene rearrangements of Ig/TCR Neoplasia residual Leucemia-linfoma linfoblástico de células precursoras Citometria de fluxo Reação em cadeia da polimerase Rearranjo gênico do linfócito T |
title_short |
Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia |
title_full |
Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia |
title_fullStr |
Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia |
title_full_unstemmed |
Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia |
title_sort |
Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia |
author |
Juliana Maria Camargos Rocha |
author_facet |
Juliana Maria Camargos Rocha Sandra Guerra Xavier Marcelo Eduardo Lima Souza Juliana Godoy Assumpção Mitiko Murao Benigna Maria de Oliveira |
author_role |
author |
author2 |
Sandra Guerra Xavier Marcelo Eduardo Lima Souza Juliana Godoy Assumpção Mitiko Murao Benigna Maria de Oliveira |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Juliana Maria Camargos Rocha Sandra Guerra Xavier Marcelo Eduardo Lima Souza Juliana Godoy Assumpção Mitiko Murao Benigna Maria de Oliveira |
dc.subject.por.fl_str_mv |
Minimal residual disease Acute lymphoblastic leukemia Flow cytometry PCR Gene rearrangements of Ig/TCR |
topic |
Minimal residual disease Acute lymphoblastic leukemia Flow cytometry PCR Gene rearrangements of Ig/TCR Neoplasia residual Leucemia-linfoma linfoblástico de células precursoras Citometria de fluxo Reação em cadeia da polimerase Rearranjo gênico do linfócito T |
dc.subject.other.pt_BR.fl_str_mv |
Neoplasia residual Leucemia-linfoma linfoblástico de células precursoras Citometria de fluxo Reação em cadeia da polimerase Rearranjo gênico do linfócito T |
description |
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatment strategies for childhood ALL result in long term remission for approximately 90% of patients. However, therapeutic response is worse among those who relapse. Several risk stratification approaches based on clinical and biological aspects have been proposed in order to intensify treatment in patients with high risk of relapse and reduce toxicity on those with greater probability of cure. The detection of residual leukemic cells (minimal residual disease, MRD) is the most important prognostic factor to identify high risk patients, allowing redefinition of chemotherapy. In the last decades, several standardized research protocols evaluated MRD using immunophenotyping by flow cytometry and/or real time quantitative polymerase chain reaction at different time points during treatment. Both methods are highly sensitive (10-3 a 10-5), but expensive, complex, and, because of that, require qualified staff and frequently are restricted to reference centers. The aim of this article was to review technical aspects of immunophenotyping by flow cytometry and real time quantitative polymerase chain reaction to evaluate MRD in ALL. |
publishDate |
2016 |
dc.date.issued.fl_str_mv |
2016 |
dc.date.accessioned.fl_str_mv |
2023-12-12T20:23:08Z |
dc.date.available.fl_str_mv |
2023-12-12T20:23:08Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/61942 |
dc.identifier.doi.pt_BR.fl_str_mv |
https://doi.org/10.4084/mjhid.2016.024 |
dc.identifier.issn.pt_BR.fl_str_mv |
2035-3006 |
dc.identifier.orcid.pt_BR.fl_str_mv |
https://orcid.org/0000-0001-8573-6313 |
url |
https://doi.org/10.4084/mjhid.2016.024 http://hdl.handle.net/1843/61942 https://orcid.org/0000-0001-8573-6313 |
identifier_str_mv |
2035-3006 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Mediterranean journal of hematology and infectious diseases |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
MED - DEPARTAMENTO DE PEDIATRIA |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/61942/1/License.txt https://repositorio.ufmg.br/bitstream/1843/61942/2/Current%20strategies%20for%20the%20detection%20of%20minimal%20residual%20disease%20in%20childhood%20acute%20lymphoblastic%20leukemia.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 b43bc464ca470f4275e09cfda71274fd |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1803589509048172544 |